Technetium-99m Pertechnetate Uptake Research Articles

Abstract 2315: Dynamic SPECT imaging of PSMA-specific CAR T cells in mice bearing prostate cancer

Abstract Immunotherapy using CAR-T-cells is acquiring an expanding role in the treatment of malignant disease. However, efficacy of solid tumour CAR-T-immunotherapy has proven inconsistent. Limitations include poor T-cell trafficking to tumour deposits, insufficient T-cell longevity in-vivo and the occurrence of both predicted and unanticipated on-target and off-target toxicity. To refine this therapeutic approach, it is desirable to develop systems that allow the monitoring of T-cell location and persistence in-vivo. A retroviral vector named PiN-4 was constructed, which co-expresses: (i) an interleukin (IL)-4-responsive chimeric cytokine receptor (4αβ); (ii) a prostate-specific membrane antigen (PSMA)-targeted CAR (P28z) and (iii) hNIS, which promotes the uptake of technetium-99m pertechnetate (99mTcO4−) in viable cells. IL-4 enriched human 4P28zN+ T-cells were administered intravenously to Nod Scid Gamma (NSG) mice bearing prostate tumour xenografts. Measurement of the tumour xenografts by bioluminescent imaging (BLI) found that only PSMA-expressing tumours responded to 4P28zN+ T-cell treatment. Longitudinal SPECT-CT imaging further confirmed this with the preferential accumulation of 4P28zN+ T-cells in PSMA-expressing tumours compared to PSMA-negative tumours. Use of NIS as a T-cell imaging reporter brings several potential advantages. It promotes receptor-mediated uptake of the inexpensive, low toxicity and clinically useful SPECT tracer, technetium-99m pertechnetate (99mTcO4−). In addition, the ectopic expression of NIS is well tolerated by host cells and hNIS functions only in viable cells. These data demonstrate proof of concept for the utility of hNIS as an imaging reporter in genetically engineered T-cells. Citation Format: Nia Emami-Shahri, Julie Foster, Jane Sosabowski, John Maher, Sophie Papa. Dynamic SPECT imaging of PSMA-specific CAR T cells in mice bearing prostate cancer. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 2315.

Illuminating cognitive dedifferentiation at the end of life

<b>1097</b> <h3><b>Objectives:</b></h3> This study examines the influence of uinary iodine excretion on thyroid technetium-99m pertechnetate uptake with Graves,hyperthyroidism patients. Background:Previous studies have shown that low plasma iodine concentrations may increase the expression of the sodium iodine symporter (NIS) and result in increased iodine uptake of thyroid. All the patient recommended to aviod iodine-riched food and iodine-containing medications prior to iodine-131 (¹³¹I) scanning in two weeks. But the efficacy of this diet as for technetium-99m pertechnetate (99mTc-P) thyroid scintigraphy is not well addressed in the Previous studies. <h3><b>Methods:</b></h3> In July 2017 to November a total of 100 newly diagnosed Graves^,hyperthyroidism patients were included into this study.All patients underwhent examinatioium-99m pertechnetate (99mTc-P) thyroid scintigraphy and the patients^,urine samples were collected for uinary iodine excretion examination,The uninary iodine concentration was measured by ductively coupled plasma mass spectrometry.Urinary creatinine was also measured for calibration of urinary iodine.The uptake ^99mTc ratio of thyroid glands (region of interest (ROI)/the neck background) was mesured after technetium-99m pertechnetate (99mTc-P) thyroid scintigraphy.Patients were divided into three groups according to the urinary iodine concentration.Group A :patients with low uinary iodine concentration(defined as a urinary iodine concentration&amp;#8804;100ug iodine/g creatinine [lg/gCr]).GroupB:Patients with medium uinary iodine concentration(defined as a urinary iodine concentration 101-249iodine/g creatinine [lg/gCr]).GroupC:Patients with gigh high uinary ugiodine concentration(defined as a urinary iodine concentration ≥250ug iodine/g creatinine [lg/gCr]). <h3><b>Results:</b></h3> All the patients^,urinary iodine concentration and ^99mTc uptake ratio Correlation analysis result show that there is a negative correlation between them.The coefficient of association is -0.24(P&lt;0.05).Group A compared with group B the patient^,uptake ^99mTc ratio of thyroid glands is higher but has no statistical significance(p&gt;0.05).Group A compared with group C the patient^,^99mTc uptake ratio of thyroid glands is higher(P&lt;0.05).Group A compared with group C the patient,uptake 99mTc ratio of thyroid glands is higher(P&lt;0.05). <h3><b>Conclusions:</b></h3> This study showed an inverse correlation between uinary iodine concentration and^99mTc ratio of thyroid glands.Excess iodine intake may supress Graves,hyperthyroidism patients ^, uptake of technetium-99m pertechnetate.

Preservation of Echogenicity in Type II Amiodarone-Induced Thyrotoxicosis: Possible Histopathological Basis

Sonographic hypoechogenicity of the thyroid in autoimmune and infective thyroiditis is well known (Fig. 1), whereas the sonographic appearance of type II amiodarone-induced thyrotoxicosis (AIT-II) has not been described. The ultrasound and scintigraphy findings of 16 consecutive patients diagnosed with AIT-II were reviewed. Thyroid echogenicity was normal in all patients (Fig. 2). Technetium-99m pertechnetate uptake was invariably reduced. AIT-II results from follicular damage and thyroid hormone leakage, a pathogenesis similar to subacute thyroiditis (SA). Subtle differences in histology defining the two conditions may explain the discrepant sonographic ap-

Blood-Brain Barrier Permeability of Human Gliomas as Determined by Quantitation of Cytoplasmic Vesicles of the Capillary Endothelium and Scintigraphic Findings

The number of cytoplasmic vesicles in the capillary endothelium was determined by ultrastructural morphometry and correlated with the uptake of technetium-99m pertechnetate used in brain scintigraphy. Ten gliomas were studied for uptake rates of 99mTc pertechnetate. Three gliomas from the different groups of uptake rates were quantitatively analyzed for cytoplasmic vesicle content. Capillaries of tumors without uptake had a low content of cytoplasmic vesicles, which was similar to that obtained in normal brain control. In tumors with low and moderate uptake rates, the cytoplasmic vesicles content increased significantly (p less than 0.05) by about 300% and 400%, respectively, as compared with that found in impermeable tumor and in normal brain. The correlation found between the cytoplasmic vesiculation of the endothelial cells in gliomas' capillaries and the uptake of 99mTc pertechnetate suggests that pinocytosis might be a factor in the uptake of the radionuclide. The present findings might be applicable to treatment with hydrophilic chemotherapeutic agents in moderate and highly permeable tumors.

Increased Uptake of Technetium-99m Pertechnetate in a Salivary Gland Cancer

Epithelioma a cellules acineuses de la parotide. Il semble que ce soit le premier cas publie

Technetium-99m pertechnetate uptake and scanning in the evaluation of thyroid function

Technetium-99m as pertechnetate is accumulated by the thyroid but not appreciably organified. In this study, a method of determining thyroidal uptake from the scintiscan is described. The mean uptake in euthyroid individuals as measured by this method was 1.73±0.85% with a normal range of 0.50–4.00%. Uptake was not affected by organic blocking agents. In a comparison of the overall accuracy of pertechnetate and 24-hr radioiodine uptakes, the pertechnetate uptake was slightly superior, with only 5.9% errors in 488 patients. Radioiodine uptakes were in error in 7.8% of 270 individuals. In hyperthyroid patients, the accuracy of the pertechnetate uptake was 89.6% while the radioiodine uptake had an accuracy of 75.0%. Both uptake determinations were highly inaccurate in hypothyroidism.

Salivary gland scanning with technetium 99m pertechnetate.

SALIVARY GLAND SCANNING WITH TECHNETIUM 99M PERTECHNETATEARTHUR S. GROVE, JR., M.D. and GIOVANNI DI CHIRO, M.D.Audio Available | Share